journal
preproof
j
u
r
n
l
p
r
e
p
r
f
fund
none
disclosur
statement
author
declar
conflict
interest
novel
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
evolv
worldwid
crisi
declar
global
pandem
world
health
organ
march
rate
spread
rang
clinic
manifest
morbid
mortal
associ
prompt
special
interest
understand
factor
predispos
individu
infect
sever
form
diseas
mani
earli
studi
china
overlap
find
addit
older
age
certain
chronic
medic
condit
includ
hypertens
type
diabet
cardiovascular
diseas
risk
factor
sever
ill
note
accord
recent
studi
divers
haplotyp
identifi
distinct
area
probabl
due
differ
sourc
exposur
howev
evid
exist
whether
haplotyp
respons
differ
clinic
manifest
diseas
pandem
spread
worldwid
affect
countri
territori
april
number
global
case
surpass
million
includ
death
unit
state
alon
report
case
death
accord
recent
studi
iceland
percentag
peopl
high
risk
infect
mainli
patient
symptom
close
contact
infect
person
recent
travel
area
major
commun
spread
test
posit
infect
approxim
comparison
percentag
infect
individu
gener
popul
remain
stabl
cours
day
note
children
ten
year
age
femal
lower
incid
infect
compar
adolesc
adult
male
respect
initi
data
incid
preval
like
chang
significantli
time
progress
pandem
expect
avail
better
test
confirm
diagnosi
well
short
longterm
immun
emerg
literatur
itali
unit
state
also
point
higher
burden
sever
diseas
individu
chronic
medic
condit
preliminari
data
unit
journal
preproof
state
identifi
diabet
common
risk
factor
infect
editori
review
clinic
observ
relat
diabet
china
itali
unit
state
next
review
pathogenesi
immun
respons
infect
outlin
propos
mechan
may
predispos
individu
diabet
infect
sever
diseas
final
highlight
area
warrant
investig
discuss
manag
consider
clinician
first
cluster
case
pneumonia
unknown
etiolog
appear
wuhan
china
late
decemb
subsequ
analysi
identifi
novel
betacoronaviru
seventh
member
coronaviru
famili
infect
human
includ
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
caus
agent
earli
singlecent
observ
studi
wuhan
individu
sever
pneumonia
describ
high
preval
chronic
ill
preval
type
diabet
individu
surviv
infect
anoth
earli
larg
observ
studi
identifi
type
diabet
common
underli
condit
patient
sever
ill
second
hypertens
metaanalysi
includ
studi
found
incid
diabet
twofold
higher
develop
sever
diseas
compar
patient
experienc
nonsever
diseas
subsequ
studi
demonstr
associ
diabet
poor
prognosi
increas
mortal
recent
retrospect
cohort
studi
patient
admit
wuhan
union
hospit
found
patient
diabet
identifi
diabet
risk
factor
sever
diseas
base
radiograph
find
biomark
inflamm
endorgan
damag
find
consist
summari
report
case
across
china
chines
center
diseas
control
cdc
show
increas
fatal
rate
individu
diabet
compar
overal
fatal
rate
addit
recent
multicent
retrospect
cohort
studi
confirm
inpati
jinyintan
hospit
wuhan
pulmonari
hospit
found
statist
signific
associ
diabet
increas
mortal
itali
sever
diseas
strain
healthcar
system
relat
noteworthi
one
recent
estim
case
fatal
rate
factor
uniqu
italian
popul
may
contribut
higher
case
fatal
rate
rel
older
popul
emerg
data
also
highlight
role
underli
chronic
cardiometabol
diseas
sever
ill
retrospect
case
seri
patient
admit
intens
care
unit
icu
lombardi
region
found
hypertens
cardiovascular
diseas
diabet
common
underli
medic
condit
italian
nation
institut
health
report
preval
diabet
patient
die
infect
suggest
diabet
may
signific
risk
factor
mortal
first
case
unit
state
confirm
januari
snohomish
counti
washington
two
earli
case
seri
critic
ill
patient
admit
icu
seattlearea
found
incid
diabet
respect
robust
studi
need
complet
preliminari
data
unit
state
cdc
march
estim
diabet
preval
underli
health
condit
individu
infect
estim
patient
requir
icu
admiss
diabet
remain
fulli
elucid
given
natur
studi
design
initi
report
whether
report
associ
independ
potenti
confound
factor
gender
age
associ
diabet
addit
extent
admiss
hospit
icu
medic
use
icu
steroid
may
contribut
increas
preval
diabet
metabol
syndromerel
comorbid
need
determin
coronavirus
positivesens
singlestrand
rna
virus
larg
kilobas
genom
packag
insid
capsid
form
nucleocapsid
protein
n
envelop
surround
helic
structur
associ
three
structur
protein
membran
protein
envelop
protein
e
involv
virion
assembl
spike
protein
mediat
entri
host
cell
protein
character
receptorj
u
r
n
l
p
r
e
p
r
f
bind
domain
rbd
subunit
facilit
bind
host
angiotensinconvert
enzym
receptor
sarscov
subunit
respons
membran
fusion
rbd
merscov
attach
host
cell
via
dipeptidyl
peptidas
rather
recent
studi
demonstr
certain
structur
chang
rbd
uniqu
result
enhanc
receptor
bind
affin
comparison
sarscov
host
cell
factor
mediat
viral
entri
two
serin
proteas
furin
activ
protein
membran
fusion
cleavag
assist
viral
process
respect
infect
occur
complex
orchestr
respons
innat
adapt
immun
system
ensu
correl
clinic
three
propos
phase
viremia
phase
acut
phase
recoveri
phase
innat
immun
respons
involv
recognit
viral
pathogenassoci
molecular
pattern
pattern
recognit
receptor
ie
tolllik
receptor
result
express
type
interferon
inflammatori
factor
potenti
macrophag
natur
killer
cell
defens
mechan
dendrit
cell
tissu
phagocyt
bridg
innat
adapt
immun
respons
activ
tlymphocyt
blymphocyt
antigenpresent
adapt
immun
system
essenti
control
persist
phase
infect
involv
product
neutral
monoclon
antibodi
viral
envelop
glycoprotein
cell
kill
viralinfect
cell
cytotox
cell
acut
phase
infect
sarscov
invad
tlymphocyt
result
apoptosi
lymphocytopenia
marker
associ
sever
outcom
specif
humor
respons
infect
investig
studi
hospit
patient
revers
transcript
polymeras
chain
reaction
rtpcr
confirm
infect
show
seroconvers
rate
total
antibodi
igm
igg
respect
note
patient
neg
antibodi
find
later
stage
blood
sampl
avail
analysi
howev
subsequ
studi
analyz
plasma
patient
recov
mild
ill
show
particip
gener
low
level
neutral
antibodi
elderli
patient
like
gener
robust
antibodi
respons
j
u
r
n
l
p
r
e
p
r
f
younger
patient
implic
regard
suscept
recurr
infect
warrant
investig
ongo
studi
expect
shed
light
topic
individu
diabet
suscept
broad
rang
infect
addit
sever
infect
may
result
less
wellcontrol
diabet
numer
factor
contribut
immun
dysfunct
individu
diabet
includ
hyperglycemia
inhibit
neutrophil
chemotaxi
alter
cytokin
product
phagocyt
cell
dysfunct
impair
tcell
mediat
immun
respons
ineffect
microbi
clearanc
relationship
known
mechan
immun
dysfunct
patient
diabet
infect
requir
investig
one
recent
studi
involv
patient
admit
suggest
hypertens
diabet
result
delay
clearanc
hm
cellular
bind
site
merscov
induc
diabet
highfat
diet
diabet
hm
mice
develop
sever
diseas
found
dysregul
immun
respons
infect
character
delay
decreas
recruit
cell
inflammatori
monocyt
macrophag
lung
tissu
addit
decreas
overal
cell
respons
infect
diabet
mice
also
display
promin
respons
increas
level
indic
alter
cytokin
profil
could
partli
respons
diseas
sever
studi
consist
prior
evid
diabet
result
shift
toward
respons
diminish
regulatori
cell
result
exagger
inflammatori
cascad
notabl
patient
infect
develop
fatal
hyperinflammatori
syndrom
resembl
secondari
hemophagocyt
lymphohistiocytosi
thought
mediat
proinflammatori
cytokin
anoth
area
scientif
clinic
interest
center
relationship
receptor
express
specif
diseas
diabet
transmembran
glycoprotein
express
cell
throughout
human
bodi
includ
upper
respiratori
tract
epithelium
type
ii
alveolar
pneumocyt
cardiac
myocyt
pancreat
islet
cell
reninangiotensinaldosteron
raa
signal
pathway
compris
angiotensinconvert
enzym
ace
metabol
angiotensin
ang
angiotensin
ii
ang
ii
convert
ang
ii
angiotensin
ang
ang
ii
vasoconstrict
inflammatori
properti
counterbalanc
vasodilatori
antiinflammatori
properti
ang
ratio
activ
ace
highli
express
lung
shown
implic
lung
oxygen
lung
injuri
acut
respiratori
distress
syndrom
ard
experiment
model
follow
sarscov
epidem
show
spike
protein
bind
result
decreas
express
receptor
lung
suggest
lung
injuri
may
mediat
higher
proport
ang
ii
rel
ang
thu
receptor
appear
conflict
role
relat
pathophysiolog
infect
one
facilit
diseas
bind
site
anoth
reduc
express
may
contribut
sever
lung
injuri
infect
effect
diabet
express
specif
tissu
need
studi
detail
experiment
model
primarili
focus
kidney
type
type
diabet
mice
shown
increas
express
earli
diseas
follow
decreas
express
later
diseas
coincid
develop
nephropathi
similarli
shown
decreas
tubul
individu
diabet
nephropathi
experiment
model
investig
effect
diabet
express
tissu
throughout
bodi
found
ratio
activ
lung
decreas
latestag
diabet
convers
recent
phenomewid
mendelian
random
studi
investig
associ
diseas
state
express
found
type
diabet
causal
associ
increas
express
lung
investig
effect
diabet
infect
warrant
guid
therapeut
approach
discuss
emerg
inform
suggest
patient
diabet
suscept
infect
risk
increas
morbid
mortal
associ
howev
argu
presenc
diabet
may
predispos
increas
risk
infect
rather
rapid
progress
wors
outcom
thu
appropri
control
larg
studi
inpati
outpati
set
need
quantifi
magnitud
associ
therapi
assess
whether
associ
causal
due
underli
confound
exampl
studi
suggest
increas
suscept
infect
individu
diabet
could
confound
greater
degre
test
popul
due
frequent
visit
emerg
depart
hospit
coexist
complic
diabet
compon
metabol
syndrom
cardiovascular
diseas
thu
necessari
clarifi
whether
patient
diabet
highli
prone
infect
poor
outcom
note
challeng
encount
qualiti
avail
pcrbase
diagnost
test
current
use
make
diagnosi
furthermor
first
antibodybas
test
diagnos
recent
infect
igm
remot
infect
igg
possibl
immun
emerg
initi
antibodybas
test
mainli
enzymelink
immunosorb
assay
elisa
character
lack
specif
due
crossreact
coronavirus
defici
need
correct
test
clinic
use
avail
need
significantli
increas
sinc
current
avail
screen
asymptomat
popul
deploy
largescal
antibodi
test
imper
understand
frequenc
infect
specif
subpopul
individu
diabet
also
obtain
accur
assess
case
fatal
rate
serolog
test
could
provid
necessari
readout
regard
efficaci
vaccin
medic
current
clinic
trial
also
essenti
part
assess
among
gener
popul
could
allow
return
work
safe
thu
inform
public
polici
decis
regard
eas
restrict
reopen
workforc
take
account
accur
wide
avail
diagnost
tool
need
expand
studi
sampl
due
fact
cellular
receptor
mani
investig
express
concern
whether
patient
treat
ace
inhibitor
acei
angiotensin
ii
typei
receptor
blocker
arb
drug
increas
express
may
exhibit
wors
prognosi
question
whether
physician
discontinu
drug
patient
take
hypertens
complic
diabet
hand
evid
emphas
protect
effect
cardiovascular
system
ard
impair
activ
may
hypothet
attenu
cardioprotect
role
exagger
inflamm
contribut
sever
lung
injuri
discuss
human
well
understood
evid
suggest
express
may
reduc
elderli
individu
hypertens
diabet
provid
argument
continu
aceisarb
clinic
trial
investig
therapeut
effect
initi
medic
sever
case
furthermor
differ
raa
inhibitor
may
demonstr
differ
effect
level
outcom
discontinu
acei
arb
may
result
advers
health
outcom
relat
poor
control
chronic
condit
area
activ
investig
epidemiolog
risk
factor
perspect
well
novel
drug
develop
point
view
moreov
multicent
observ
studi
conduct
estim
preval
case
fatal
ratio
diseas
appear
differ
among
differ
popul
potenti
explan
observ
differ
includ
measur
error
sinc
denomin
ratio
affect
qualiti
number
measur
case
genet
suscept
popul
interest
differenti
virul
j
u
r
n
l
p
r
e
p
r
f
known
haplotypesvari
viru
addit
experiment
rigor
clinic
trial
vital
import
clarifi
explor
find
observ
studi
furthermor
trial
use
multiom
approach
big
data
analyt
urgent
need
examin
characterist
subpopul
identifi
potenti
risk
factor
ie
sex
race
ethnic
presenc
preexist
disord
comorbid
intervent
trial
also
focu
efficaci
safeti
differ
type
raa
inhibitor
elucid
role
mechan
action
diseas
milieu
whether
differ
class
antidiabet
drug
may
affect
level
inhibitor
reduc
risk
infect
modifi
diseas
progress
investig
indepth
understand
diseas
crucial
develop
effect
vaccin
therapeut
strategi
potenti
benefit
sever
agent
current
investig
ie
hydroxychloroquin
chloroquin
azithromycin
corticosteroid
antiinflammatori
agent
antivir
drug
convalesc
plasma
transfus
numer
compound
develop
random
clinic
trial
design
examin
safeti
efficaci
drug
chemoprophylaxi
treatment
includ
patient
diabet
possibl
quick
interim
analysi
studi
consid
global
attent
focus
pandem
urgent
request
emerg
access
potenti
therapi
understand
temptat
use
drug
without
fulli
proven
safeti
efficaci
diseas
result
greater
emphasi
drugevalu
process
evidencebas
decis
make
need
protect
patient
possibl
ineffect
drug
also
potenti
unsaf
treatment
may
induc
complic
side
effect
trial
longterm
follow
essenti
evalu
effect
differ
therapeut
strategi
patientcent
outcom
intermediateterm
longterm
mortal
studi
also
design
examin
longterm
cardiometabol
sequela
infect
among
individu
recov
note
one
small
studi
evalu
individu
year
recoveri
sarscov
infect
found
higher
amount
alter
glucos
lipid
metabol
signific
differ
serum
metabolom
compar
agematch
healthi
control
metabol
issu
call
paper
letter
editor
enhanc
scientif
dialogu
facilit
dissemin
critic
need
use
inform
area
time
acknowledg
urgent
need
inform
global
public
health
crisi
led
increas
number
publish
paper
data
sever
limit
includ
sampl
issu
methodolog
constraint
limit
peerreview
process
potenti
public
research
bia
may
affect
valid
find
interpret
essenti
futur
studi
predefin
standard
criteria
regard
studi
hypothesi
sampl
popul
clinic
syndrom
diseas
sever
patientcent
outcom
observ
intervent
studi
thu
order
elucid
impact
diabet
mellitu
risk
factor
well
explor
best
prophylact
therapeut
strategi
highrisk
popul
critic
design
conduct
highqual
robust
observ
studi
clinic
trial
given
current
situat
pauciti
robust
scientif
evid
lack
specif
treatment
becom
crucial
worldwid
health
problem
present
quarantin
isol
social
distanc
stringent
restrict
domest
intern
travel
effect
prevent
strategi
along
practic
good
hygien
howev
due
potenti
lack
access
medic
suppli
individu
diabet
may
experi
difficulti
acquir
essenti
medic
suppli
well
consum
medic
devic
insulin
alcohol
wipe
glucos
test
strip
etc
result
metabol
dysregul
inadequ
control
coexist
cardiometabol
condit
hypertens
dyslipidemia
may
occur
patient
diabet
notabl
also
express
pancreat
liver
tissu
may
potenti
target
lead
worsen
hyperglycemia
infect
accord
hypothesi
acut
ill
per
se
may
worsen
glycem
control
given
individu
diabet
especi
comorbid
complic
consid
highrisk
patient
evid
risk
factor
hyperglycemia
hypertens
optim
clinician
proactiv
address
need
patient
use
telemedicin
technolog
includ
phone
call
video
visit
avail
unit
state
govern
notabl
decreas
regulatori
threshold
make
video
health
visit
easier
provid
pandem
anticip
establish
care
technolog
advanc
mean
may
last
impact
treat
follow
patient
diabet
longterm
patient
physician
adopt
benefit
novel
technolog
advanc
innov
public
health
intervent
also
explor
mobil
phone
contact
trace
app
could
use
strategi
mitig
presymptomat
transmiss
also
consid
limit
theoret
model
minimum
number
regist
potenti
privaci
complianc
issu
ethic
requir
health
care
provid
gener
use
telemedicin
telehealth
servic
minim
physic
contact
simultan
provid
individu
care
support
feedback
moreov
also
ensur
close
monitor
mainten
healthi
lifestyl
practic
treatment
adher
aim
remot
address
rise
health
issu
effici
time
manner
due
uncertain
situat
extrem
challeng
circumst
individu
may
undergo
physic
health
deterior
also
may
experi
variou
anxieti
psycholog
pressur
distress
vulner
multidisciplinari
group
experienc
profession
health
social
servic
assist
patient
diabet
well
famili
caregiv
take
advantag
new
communicationbas
social
network
platform
immedi
manag
consider
surround
medic
acei
arb
continu
debat
investig
due
lack
strong
evid
given
benefici
organprotect
effect
acei
arb
well
potenti
advers
outcom
cardiovascular
system
heart
failur
societi
america
american
colleg
cardiolog
american
heart
associ
well
european
societi
cardiolog
recommend
discontinu
raa
inhibitor
note
sever
clinic
trial
underway
examin
safeti
efficaci
raa
inhibitor
number
report
regard
role
corticosteroid
sever
acut
ill
due
corticosteroid
may
attenu
pulmonari
j
u
r
n
l
p
r
e
p
r
f
inflamm
subsequ
acut
lung
injuri
reduc
inflammatori
respons
modul
activ
immun
system
howev
concern
exist
whether
corticosteroid
use
associ
viral
rebound
prolong
replic
increas
rate
mechan
ventil
mortal
therefor
accord
corticosteroid
treatment
routin
recommend
therapeut
option
pneumonia
outsid
clinic
trial
point
would
also
like
note
base
current
propos
mechan
pathogenesi
recombin
solubl
human
recent
receiv
regulatori
approv
studi
context
phase
ii
clinic
trial
treat
patient
sever
allevi
detriment
effect
acut
inflamm
lung
may
exhibit
protect
role
acut
lung
injuri
ard
induc
due
similar
human
viru
bind
solubl
inhibit
entri
human
cell
serv
decoy
receptor
opinion
base
mechan
action
believ
promis
compound
among
medic
current
develop
context
also
note
activ
molecul
downstream
essenti
viral
entri
primari
target
cell
addit
viral
spread
pathogenesi
infect
host
accord
recent
data
camostat
mesyl
transmembran
serin
proteas
serin
inhibitor
develop
treatment
acut
pancreat
activ
prevent
cellular
entri
viru
data
regard
addit
drug
class
nafamostat
also
expect
near
futur
plan
trial
drug
promis
therapeut
agent
data
urgent
need
specif
treatment
current
approv
ongo
pandem
rapidli
evolv
fast
effici
also
unbias
reliabl
valid
studi
paramount
import
provid
evidencebas
inform
guidanc
unansw
question
time
close
monitor
data
crucial
identifi
best
strategi
term
prevent
earli
diagnosi
treatment
global
challeng
health
problem
given
sever
virus
increas
infect
virul
lethal
emerg
past
three
decad
hot
spot
around
world
coordin
public
health
effort
center
prevent
transmiss
zoonot
diseas
human
well
earli
detect
potenti
threat
need
avoid
similar
j
u
r
n
l
p
r
e
p
r
f
futur
outbreak
ultim
nation
intern
organ
includ
need
come
togeth
commun
priorit
global
prepared
initi
ensur
event
like
occur
never
earli
start
build
foundat
effect
prevent
address
futur
threat
fight
evolv
danger
pandem
